Angiogenesis, the metabolic syndrome and heart disease: Is there a connection?

Journal of Internal Medicine

Volumn 268, Issue 4, 2010, Pages 312-315

  Blann, A D ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; INSULIN; PLACENTAL GROWTH FACTOR; TROPONIN T; VASCULOTROPIN;

ANGIOGENESIS; CARDIOMYOPATHY; CARDIOVASCULAR RISK; EDITORIAL; HEART DISEASE; HEART INFARCTION; HUMAN; HYPERINSULINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; LABORATORY DIAGNOSIS; METABOLIC SYNDROME X; METASTASIS; PRIORITY JOURNAL; TACHYCARDIA;

HEART DISEASES; HUMANS; METABOLIC SYNDROME X; NEOVASCULARIZATION, PATHOLOGIC;

EID: 77956331432     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2010.02271.x     Document Type: Editorial

References (39)

1. Gordon ES. Metabolic aspects of obesity. Adv Metab Disord 1970 4 : 229 296.
2. Berchtold P, Sims EA, Horton ES, Berger M. Obesity and hypertension: epidemiology, mechanisms, treatment. Biomed Pharmacother 1983 37 : 251 258.
3. Lind L, Lithell H. Hypertension, hyperlipidemia, insulin resistance and obesity: parts of a metabolic syndrome. Blood Press Suppl 1992 4 : 49 54.
4. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993 44 : 121 131.
5. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998 81 (4A 18B 25B.
6. Müller-Wieland D, Kotzka J, Knebel B, Krone W. Metabolic syndrome and hypertension: pathophysiology and molecular basis of insulin resistance. Basic Res Cardiol 1998 93 (Suppl 2 131 134.
7. Timar O, Sestier F, Levy E. Metabolic syndrome X: a review. Can J Cardiol 2000 16 : 779 789.
8. Grundy SM, Cleeman JI, Daniels SR et al. American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome. Circulation 2005 112 : 2735 2752.
9. Kahn R, Buse J, Ferrannini E, Stern M. American Diabetes Association; European Association for the Study of Diabetes. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005 28 : 2289 2304.
10. Andersen P. Hypercoagulability and reduced fibrinolysis in hyperlipidemia: relationship to the metabolic cardiovascular syndrome. J Cardiovasc Pharmacol 1992 8 : S29 31.
11. Ridker PM, Wilson PW, Grundy SM. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk? Circulation 2004 109 : 2818 2825.
12. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009 120 : 1640 1645.
13. Matsuzawa Y, Funahashi T, Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann N Y Acad Sci 1999 92 : 146 154.
14. Sonnenberg GE, Krakower GR, Kissebah AH. A novel pathway to the manifestations of metabolic syndrome. Obes Res 2004 12 : 180 186.
15. Ammann P, Pfisterer M, Fehr T, Rickli H. Raised cardiac troponins. Causes extend beyond acute coronary syndromes. Br Med J 2004 328 : 1028 1029.
16. Sudoh T, Minamino N, Kangawa K, Matsuo H. Brain natriuretic peptide-32: N-terminal six amino acid extended form of brain natriuretic peptide identified in porcine brain. Biochem Biophys Res Commun 1988 155 : 726 732.
17. Thibault G, Garcia R, Cantin M, Genest J. Atrial natriuretic factor. Characterization and partial purification. Hypertension 1983 5 : I75 80.
18. Richards AM, Nicholls MG, Espiner EA et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003 107 : 2786 2792.
19. Tello-Montoliu A, Marín F, Roldán V et al. A multimarker risk stratification approach to non-ST elevation acute coronary syndrome: implications of troponin T, CRP, NT pro-BNP and fibrin D-dimer levels. J Intern Med 2007 262 : 651 658.
20. Blankenberg S, Zeller T, Saarela O et al. MORGAM Project. Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 2010 121 : 2388 2397.
21. Palazzuoli A, Gallotta M, Quatrini I, Nuti R. Natriuretic peptides (BNP and NT-proBNP): measurement and relevance in heart failure. Vasc Health Risk Manag. 2010 6 : 411 418.
22. Folkman J. Tumor angiogenesis. Adv Cancer Res 1974 19 : 331 358.
23. Ware JA, Simons M. Angiogenesis in ischemic heart disease. Nat Med 1997 3 : 158 164.
24. Di Stefano R, Felice F, Balbarini A. Angiogenesis as risk factor for plaque vulnerability. Curr Pharm Des 2009 15 : 1095 1106.
25. Blann AD, Belgore FM, McCollum CN, Silverman S, Lip PL, Lip GY. Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or Type II diabetes. Clin Sci 2002 102 : 187 194.
26. Belgore FM, Blann AD, Li-Saw-Hee FL, Beevers DG, Lip GY. Plasma levels of vascular endothelial growth factor and its soluble receptor (sFlt-1) in essential hypertension. Am J Cardiol 2001 87 : 805 807.
27. McLaren M, Elhadd TA, Greene SA, Belch JJ. Elevated plasma vascular endothelial cell growth factor and thrombomodulin in juvenile diabetic patients. Clin Appl Thromb Hemost 1999 5 : 21 4.
28. Isner JM. Therapeutic angiogenesis: a new frontier for vascular therapy. Vasc Med 1996 1 : 79 87.
29. Virmani R, Kolodgie FD, Burke AP et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005 25 : 2054 2061.
30. Khurana R, Simons M, Martin JF, Zachary IC. Role of angiogenesis in cardiovascular disease: a critical appraisal. Circulation 2005 112 : 1813 1824.
31. Siervo M, Ruggiero D, Sorice R et al. Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. J Int Med 2010 268 : 338 347.
32. Belgore FM, Lip GY, Blann AD. Vascular endothelial growth factor and its receptor, Flt-1, in smokers and non-smokers. Br J Biomed Sci 2000 57 : 207 213.
33. Wada H, Satoh N, Kitaoka S et al. Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. Atherosclerosis 2010 208 : 512 517.
34. Cassidy A, Chiuve SE, Manson JE, Rexrode KM, Girman CJ, Rimm EB. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009 29 : 134 139.
35. Khurana R, Moons L, Shafi S et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005 111 : 2828 2836.
36. Roncal C, Buysschaert I, Gerdes N et al. Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res 2010 86 : 29 36.
37. Pilarczyk K, Sattler KJ, Galili O et al. Placenta growth factor expression in human atherosclerotic carotid plaques is related to plaque destabilization. Atherosclerosis 2008 196 : 333 340.
38. Sainz J, Sata M. Is PlGF a plaque growth factor? Cardiovasc Res 2010 86 : 4 5.
39. Nwose EU, Richards RS, McDonald S, Jelinek HF, Kerr PG, Tinley P. Assessment of diabetic macrovascular complications: a prediabetes model. Br J Biomed Sci 2010 67 : 59 66.